Researchers Await Sale Of VW Stock

WEST BERLIN—Europe’s biggest private science foundation, derived from Volkswagenwerk AG, is counting on a rebound of world financial markets to secure the capital it needs to meet its ambitious goals for the support of research. A planned November 9 sale of the government’s 16 percent share in the auto maker’s stock has been postponed indefinitely, West German Finance Minister Gerhard Stoltenberg announced earlier this month. The value of the stock package is roughly $2

Written byRichard Sietmann
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WEST BERLIN—Europe’s biggest private science foundation, derived from Volkswagenwerk AG, is counting on a rebound of world financial markets to secure the capital it needs to meet its ambitious goals for the support of research. A planned November 9 sale of the government’s 16 percent share in the auto maker’s stock has been postponed indefinitely, West German Finance Minister Gerhard Stoltenberg announced earlier this month. The value of the stock package is roughly $290 million now. Its market value was five times higher before last month’s crash.

The VW Foundation needs a substantial boost in its total worth, which last year stood at $2.15 billion, to achieve its goals, said Werner Remmers, chairman of its board of regents. In its 25-year history it has spent $4.5 billion on almost 16,000 research, projects. The sciences received half of last year’s $225 million distribution, with the humanities being given 41 percent and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies